Working… Menu

Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-913 in Subjects With MPS II

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03041324
Recruitment Status : Terminated (All nine subjects dosed in the study have rolled over to the Long-Term Follow-up Study IVPRP-LT01 [NCT04628871])
First Posted : February 2, 2017
Last Update Posted : June 8, 2021
Information provided by (Responsible Party):
Sangamo Therapeutics

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : May 7, 2021
Actual Study Completion Date : May 7, 2021